Biotechnology Smart Contracts Regulation In Russia.

1. Introduction

Biotechnology Smart Contracts Regulation in Russia concerns the legal regulation of computer-programmed agreements used in biotechnology research, pharmaceutical manufacturing, genetic testing, clinical trials, biological-data management, medical-device development, DNA sequencing, vaccine distribution and intellectual-property licensing.

A smart contract is a digital mechanism that automatically performs specified contractual operations when predetermined conditions are satisfied. For example, a biotechnology company may use a smart contract to release payment to a research laboratory after the laboratory uploads verified clinical-trial results.

In Russia, smart contracts are not governed by one comprehensive biotechnology-specific statute. Their legal treatment is derived from several areas of law, including:

Civil Code of the Russian Federation.

Federal Law No. 259-FZ of 31 July 2020 on Digital Financial Assets and Digital Currency.

Federal Law No. 63-FZ of 6 April 2011 on Electronic Signatures.

Federal Law No. 152-FZ of 27 July 2006 on Personal Data.

Federal Law No. 61-FZ of 12 April 2010 on Circulation of Medicines.

Federal Law No. 323-FZ of 21 November 2011 on the Fundamentals of Health Protection.

Federal Law No. 86-FZ of 22 June 1998 on Medicinal Products (historical legislation, subsequently replaced by the 2010 medicines framework).

The central legal issue is whether automated contractual performance can satisfy Russian requirements concerning consent, contractual validity, evidence, privacy, safety, liability and regulatory supervision.

2. Legal Framework Governing Smart Contracts in Russia

A. Civil Code of the Russian Federation

The Civil Code provides the principal legal foundation for smart-contract arrangements.

Important provisions include:

ProvisionLegal significance
Article 160Written transactions and electronic methods of expressing intention
Article 309Proper performance of contractual obligations, including performance under agreed conditions
Article 310Restrictions on unilateral refusal to perform obligations
Article 421Freedom of contract
Article 432Essential conditions for concluding contracts
Article 434Forms of contracts
Article 435Offer and contractual proposal
Article 438Acceptance of an offer
Article 450Amendment and termination of contracts

Article 309(2) is particularly important because it recognises that contractual obligations may be performed when specified circumstances arise without a separate additional expression of intention by the parties, through information technologies, provided the contractual arrangement satisfies the applicable statutory requirements.

This provides a legal foundation for automated performance.

Example: A Russian pharmaceutical manufacturer enters into an agreement with a biotechnology laboratory. The agreement provides that payment will automatically be released after an independent laboratory verifies the agreed quality standards. The smart contract can execute the payment condition once the required verification is recorded.

However, the code itself does not automatically establish every element of contractual validity. The parties must still establish consent, contractual obligations, lawful subject matter and the applicable form of agreement.

B. Federal Law No. 259-FZ of 31 July 2020

The Federal Law on Digital Financial Assets and Digital Currency is important where biotechnology agreements involve digital financial assets and automated transactions.

Its provisions address:

Issuance of digital financial assets.

Recording and transfer of digital rights.

Operation of information systems.

Automated performance of obligations.

Legal recognition of digital records.

Article 4(2) is especially relevant because it contemplates transactions in which obligations are performed when specified circumstances occur without a separately expressed additional intention to perform.

Nevertheless, digital financial assets must be distinguished from ordinary smart-contract software. A smart contract can automate an ordinary contractual obligation without necessarily involving a digital financial asset.

Another important restriction is Article 4(10), which generally prohibits using digital financial assets as payment for goods and services, subject to statutory exceptions. Consequently, a biotechnology company cannot simply assume that a digital token can lawfully replace ordinary payment for pharmaceutical products or laboratory services.

The Bank of Russia explains that digital financial assets can use distributed-ledger technology to automate transactions, while also distinguishing them from ordinary payment instruments.

Consultant Plus+1

 

C. Federal Law No. 63-FZ of 6 April 2011: Electronic Signatures

Electronic signatures are important when biotechnology companies execute digital agreements.

The law recognises different categories of electronic signatures, including simple, enhanced non-qualified and enhanced qualified electronic signatures.

They can be used for:

Research collaboration agreements.

Pharmaceutical supply contracts.

Clinical-trial documentation.

Laboratory service agreements.

Biotechnology licensing arrangements.

Electronic approvals and contractual amendments.

For transactions requiring a particular legal form, the parties must ensure that the chosen electronic signature satisfies the applicable statutory requirements.

D. Federal Law No. 152-FZ of 27 July 2006: Personal Data

This legislation is particularly important because biotechnology smart contracts may process:

Genetic information.

DNA sequencing records.

Medical histories.

Clinical-trial participant information.

Biological sample identifiers.

Patient treatment records.

Article 5 establishes principles concerning lawful purposes, data minimisation and limitations on personal-data processing. Article 9 regulates consent.

A major technical difficulty arises because blockchain records may be difficult to amend or erase, whereas personal-data legislation requires compliance with applicable correction, deletion and processing restrictions.

A safer arrangement is to store personal information in a protected external database and place only non-identifying verification records or cryptographic references on the blockchain.

CIS Legislation+1

E. Federal Law No. 86-FZ of 5 July 1996: Genetically Engineered Activities

This law regulates genetically engineered activities and associated environmental and health-protection issues.

It is particularly relevant to smart contracts used in:

Genetically modified organism research.

Gene-editing projects.

Biotechnology manufacturing.

Genetic-data management.

Biological-material transfers.

An important recent development is Article 13.2, introduced in 2026, which restricts the transfer of human genetic data obtained through population genetic and/or immunological research, subject to specified exceptions.

A smart contract cannot override these restrictions merely because the parties have digitally agreed to data sharing.

CIS Legislation+1

 

3. Application of Smart Contracts in Biotechnology

1. Pharmaceutical manufacturing agreements

Smart contracts can automate payments between pharmaceutical manufacturers, raw-material suppliers and quality-testing laboratories.

For example, a contract may release payment only after the manufacturer receives a valid quality-control certificate.

Legal requirements include compliance with medicines legislation, contractual obligations, product-quality standards and applicable manufacturing requirements.

2. Clinical-trial agreements

Clinical-trial sponsors may use smart contracts to manage payments to hospitals, research organisations and laboratories.

Automated conditions may include:

Completion of a research milestone.

Verification of clinical-trial documentation.

Confirmation of regulatory approval.

Submission of monitoring reports.

Completion of an agreed research phase.

However, automated payments must not undermine informed consent, participant protection, ethical review or the right to withdraw where applicable.

3. Genetic-data sharing agreements

Biotechnology organisations may use smart contracts to control authorised access to genetic datasets.

For example, a research institution could grant a university temporary access to a genetic dataset following verification of its research authorisation.

The system must comply with Russian genetic-data legislation, personal-data protection requirements and restrictions on international transfers.

4. Biotechnology intellectual-property licensing

Smart contracts can automate royalty payments for patented biotechnology inventions.

Examples include:

Gene-editing technologies.

Pharmaceutical formulations.

DNA sequencing technologies.

Biological manufacturing processes.

Diagnostic technologies.

Russian Civil Code provisions concerning intellectual property and licensing remain applicable. An automated royalty calculation does not replace the need for a legally valid licence.

5. Biological sample supply agreements

Smart contracts may record the collection, storage, transfer and receipt of biological samples.

However, the blockchain entry is not itself proof that the sample was collected lawfully, that consent was valid, or that the sample satisfies applicable safety requirements.

4. Important Case Laws and Judicial Principles

There is an important distinction in Russian jurisprudence: general contractual principles are established by the courts, but there is limited publicly identified case law specifically addressing blockchain smart contracts in biotechnology. The following authorities are relevant by analogy and should not be misrepresented as biotechnology-specific judgments.

Case 1. Supreme Court of the Russian Federation – Plenum Resolution No. 49 of 25 December 2018

Subject: Formation and interpretation of contracts

This resolution explains how Russian courts determine whether a legally binding contract has been concluded.

Important principles:

A contract is concluded when the parties agree on all essential conditions.

Acceptance may be demonstrated through conduct.

Electronic exchanges and other forms of communication can demonstrate contractual intention.

Contractual terms must be interpreted by considering the parties' actual intentions and the agreement as a whole.

Application to biotechnology: If a biotechnology company accepts a research proposal through an electronic platform and the parties subsequently perform their obligations through an automated system, the court may examine the electronic communications, platform records and actual conduct to establish whether a binding contract exists.

cis-legislation.com+1

Case 2. Second Cassation Court of General Jurisdiction – Case No. 88-9830/2023

Subject: Electronic contracting and automated transactions

This decision is cited in secondary legal scholarship discussing the Russian legal treatment of smart contracts and automated contractual transactions.

Its relevance is the broader judicial examination of contractual relationships involving digital systems and the importance of identifying the parties' legally significant expressions of intention.

Application to biotechnology: A dispute involving automated research payments could require examination of electronic records, the underlying agreement and evidence that the programmed conditions were actually satisfied.

Citation caution: The secondary publication identifies the decision as dated 25 April 2022 while giving the case number 88-9830/2023. That apparent date and numbering inconsistency should be checked against the original judicial record before using it as a formal legal citation. It should not be presented as a definitive biotechnology smart-contract precedent.

russianlawjournal.org

 

Case 3. Supreme Court of the Russian Federation – Case No. 45-КГ21-24 (2022)

Subject: Acceptance of contractual terms

This decision is discussed in connection with paragraph 12 of Plenum Resolution No. 49.

The relevant principle is that acceptance must demonstrate agreement with the proposed contractual conditions. Conduct that is consistent with an existing obligation does not necessarily establish acceptance of a new contractual arrangement.

Application to biotechnology: A laboratory's use of a digital research platform should not automatically be treated as acceptance of every new contractual condition introduced through a software update. The company must establish valid acceptance of the relevant terms.

CasusLegal review+1

 

Case 4. Supreme Court of the Russian Federation – Case No. 46-КГ24-1 (2024)

Subject: Unilateral cancellation of digital transactions

This decision concerns an online-store transaction in which an order was cancelled after payment because of an alleged technical pricing error.

The relevant principle is that a party cannot necessarily escape contractual obligations simply by refunding the payment or invoking a technical error.

Application to biotechnology: A pharmaceutical supplier should not assume that an automated cancellation or refund automatically terminates an otherwise binding supply agreement. The validity of cancellation must be assessed under the applicable contractual and statutory rules.

CasusLegal review

 

Case 5. Supreme Court of the Russian Federation – Case No. 5-КГ25-118 (2025)

Subject: Contract formation through conduct

This decision is discussed in the legal analysis of Plenum Resolution No. 49.

The relevant principle is that a contract may be established through correspondence, actual performance, receipts and other evidence, even when the parties have not executed one consolidated written document.

Application to biotechnology: A biotechnology research collaboration may be legally binding where the parties' electronic communications and subsequent performance establish agreement on the essential contractual terms.

CasusLegal review

 

5. Arbitration and Smart-Contract Disputes

An additional development is the establishment of specialised mechanisms for digital-economy disputes.

The Arbitration Centre at the Russian Union of Industrialists and Entrepreneurs (RSPP) has a specialised Panel for Digital Economy Disputes.

Its stated jurisdiction includes disputes concerning:

Blockchain-based transactions.

Digital assets.

Automated contractual performance.

Smart-contract transactions.

Digital identification.

Personal-data processing and security.

This is particularly relevant to biotechnology businesses using distributed-ledger technology for pharmaceutical supply chains, research collaboration and digital intellectual-property transactions.

However, institutional arbitration is not the same as a judgment of a Russian state court. The arbitration agreement, applicable arbitration rules and statutory limitations must be considered.

Arbitration Centre at RSPP

 

6. Regulatory Responsibilities of Biotechnology Companies

Russian biotechnology companies using smart contracts must consider several regulatory responsibilities.

Regulatory areaPrincipal obligation
Contract lawValid consent and enforceable contractual terms
Data protectionLawful processing of personal and genetic data
Medical researchParticipant protection and ethical requirements
PharmaceuticalsCompliance with medicines regulation
Intellectual propertyValid patent and licensing arrangements
Electronic signaturesLegally sufficient electronic authentication
Digital financial assetsCompliance with Law No. 259-FZ
Genetic engineeringCompliance with Law No. 86-FZ

Important regulatory authorities

Ministry of Health of the Russian Federation.

Federal Service for Surveillance in Healthcare (Roszdravnadzor).

Federal Service for Supervision of Communications, Information Technology and Mass Media (Roskomnadzor).

Bank of Russia.

Federal Service for Veterinary and Phytosanitary Surveillance (Rosselkhoznadzor), where relevant.

7. Major Legal Challenges

A. Irreversibility of blockchain records

Blockchain transactions may be difficult to reverse. However, Russian contract law recognises circumstances in which agreements may be challenged, terminated or declared invalid.

Therefore, smart-contract architecture should include procedures for correcting errors, suspending execution and handling disputes.

B. Incorrect scientific information

A smart contract cannot independently establish whether scientific information is accurate.

For example, an automated payment might be released after a laboratory uploads a certificate that subsequently proves fraudulent.

The contract should therefore identify authorised verification bodies and allocate responsibility for inaccurate information.

C. Protection of genetic information

Genetic information creates particularly serious compliance issues. The 2026 amendment introducing Article 13.2 of Law No. 86-FZ makes certain transfers of genetic data obtained from population genetic and immunological research subject to strict prohibitions and exceptions.

A blockchain system must not provide unauthorised foreign parties with access to protected information.

Consultant Plus+1

 

D. Algorithmic errors

If a smart contract releases money incorrectly because of a programming error, the parties may dispute responsibility.

The agreement should specify:

Responsibility for software development.

Procedures for independent audits.

Liability for programming defects.

Emergency suspension mechanisms.

Compensation for financial losses.

Dispute-resolution procedures.

E. Cross-border biotechnology transactions

International biotechnology agreements may involve Russian companies, foreign universities, pharmaceutical manufacturers and overseas research laboratories.

These transactions raise questions of governing law, jurisdiction, international data transfers, sanctions compliance and intellectual-property protection.

A smart contract does not eliminate the need to determine which country's law governs the underlying agreement.

8. Model Compliance Structure for a Biotechnology Smart Contract

A Russian biotechnology company should consider incorporating the following contractual safeguards:

Contractual elementRecommended legal protection
IdentificationVerified identities of all parties
ConsentRecorded electronic agreement
Research milestonesClearly defined performance conditions
Data accessAuthorised and restricted access
PaymentsLawful payment mechanism
Scientific verificationIndependent laboratory certification
Intellectual propertyExpress ownership and licensing provisions
ErrorsSuspension and correction procedures
LiabilityAllocation of contractual and statutory liability
DisputesRussian courts or a valid arbitration arrangement

Illustrative example

A Russian biotechnology company enters into a smart-contract agreement with a university to develop a gene-editing technology.

The agreement provides that:

The university completes the agreed research stage.

An independent laboratory verifies the results.

The authorised research organisation uploads the verification certificate.

The system records completion of the milestone.

The company releases the agreed payment through a lawful payment mechanism.

Disputes concerning scientific accuracy or contractual performance are resolved under the agreed dispute-resolution provisions.

The smart contract facilitates performance, but the underlying legal agreement continues to determine the parties' rights and responsibilities.

9. Critical Legal Analysis

Russian law provides a foundation for the use of smart contracts through its general civil-law rules and specific digital-finance legislation.

Nevertheless, biotechnology presents additional difficulties because smart contracts interact with scientific evidence, medical confidentiality, genetic information, intellectual property and public-health regulation.

Three legal principles are particularly important:

Technological neutrality: The use of blockchain does not exempt a biotechnology company from ordinary contractual and regulatory obligations.

Human accountability: Automated execution does not eliminate the responsibility of researchers, manufacturers, software developers or contracting parties.

Regulatory supremacy: A smart contract cannot authorise an activity prohibited by Russian legislation.

There is also an important distinction between using smart contracts to automate ordinary commercial agreements and issuing digital financial assets. The two activities may involve different legal requirements.

10. Conclusion

Biotechnology Smart Contracts Regulation in Russia is an emerging intersection of civil law, digital-finance regulation, data protection, pharmaceutical regulation and biotechnology governance.

The Civil Code, particularly Articles 160 and 309, provides a foundation for electronic transactions and automated contractual performance. Federal Law No. 259-FZ provides additional rules where digital financial assets and relevant information systems are involved.

The Supreme Court's Plenum Resolution No. 49 of 2018 supplies important principles for determining contractual formation, acceptance and interpretation. Other judicial decisions concerning electronic transactions and contractual performance provide supplementary guidance.

However, Russia does not yet have a comprehensive biotechnology-specific smart-contract statute or a clearly established body of reported judgments resolving biotechnology smart-contract disputes.

The future regulatory challenge will be to reconcile automated contractual execution with scientific reliability, genetic-data protection, patient rights, intellectual-property ownership and effective judicial remedies.

11. Important Legal References and Research Sources

Russian Civil Code – contractual provisions.

Federal Law No. 259-FZ – Digital Financial Assets.

Federal Law No. 152-FZ – Personal Data.

Federal Law No. 86-FZ – Genetically Engineered Activities.

Bank of Russia – Digital Financial Assets.

Supreme Court Plenum Resolution No. 49 of 25 December 2018.

Russian Law Journal – Smart Contracts Beyond the Code.

RSPP Arbitration Centre – Digital Economy Disputes.

Academic research note: The statutory framework and case-law principles should be distinguished from direct judicial precedents. The cases discussed above are general contractual authorities, not findings that Russian courts have specifically adjudicated biotechnology smart-contract disputes.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT